International Clinical Trial: Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07211958) titled 'Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation' on Sept. 30.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Syndax Pharmaceuticals

Condition: Acute Myeloid Leukemias

Intervention: Drug: Revumenib Drug: Placebo

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: December 2025

Target Sample Size: 468

To know more, v...